Climb Bio, Inc. Files 8-K on Material Agreements
Ticker: CLYM · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1768446
Sentiment: neutral
Topics: material-agreement, financial-results, corporate-update
TL;DR
Climb Bio (formerly Eliem) filed an 8-K on Jan 8, 2025, covering material agreements and financial results.
AI Summary
On January 8, 2025, Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) filed an 8-K report detailing a material definitive agreement, results of operations, and other events. The company, incorporated in Delaware with its principal executive offices in Wellesley Hills, Massachusetts, operates in the Pharmaceutical Preparations sector.
Why It Matters
This 8-K filing signals significant corporate actions and financial updates for Climb Bio, Inc., which could impact investors and the pharmaceutical sector.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price and future prospects.
Key Numbers
- 001-40708 — SEC File Number (Identifies the company's filing with the SEC)
- 83-2273741 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Climb Bio, Inc. (company) — Registrant
- Eliem Therapeutics, Inc. (company) — Former company name
- January 8, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Wellesley Hills, Massachusetts (location) — Address of Principal Executive Offices
FAQ
What specific material definitive agreement was entered into by Climb Bio, Inc. on or before January 8, 2025?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What are the key results of operations and financial conditions reported by Climb Bio, Inc. in this 8-K?
The filing states that results of operations and financial condition are items reported, but the specific financial details are not included in the provided text.
What other events are being reported by Climb Bio, Inc. in this 8-K filing?
The filing lists 'Other Events' as an item information category, but the specific nature of these events is not detailed in the provided text.
When did Climb Bio, Inc. change its name from Eliem Therapeutics, Inc.?
The filing states the date of the name change was February 19, 2019.
What is the primary business of Climb Bio, Inc. according to its Standard Industrial Classification?
Climb Bio, Inc. is classified under Pharmaceutical Preparations [2834].
Filing Stats: 1,809 words · 7 min read · ~6 pages · Grade level 16.6 · Accepted 2025-01-10 08:08:38
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share CLYM The Nasdaq Stock Mar
- $9.0 million — mpany is obligated to pay to Mabworks a $9.0 million upfront payment, a total of up to $30.0
- $30.0 million — llion upfront payment, a total of up to $30.0 million upon the achievement of certain develop
- $832 million — a Licensed Product and a total of up to $832 million upon the achievement of certain commerc
- $212.9 million — December 31, 2024, it had approximately $212.9 million in cash, cash equivalents and marketabl
Filing Documents
- d851032d8k.htm (8-K) — 36KB
- 0001193125-25-004129.txt ( ) — 162KB
- clym-20250108.xsd (EX-101.SCH) — 3KB
- clym-20250108_lab.xml (EX-101.LAB) — 18KB
- clym-20250108_pre.xml (EX-101.PRE) — 11KB
- d851032d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations, plans and prospects for the Company; expectations regarding the therapeutic benefits, clinical potential and clinical development of budoprutug and CLYM116; plans to optimize the administration of budoprutug; the anticipated benefits of the Agreement; the sufficiency of the Company's cash resources for the period anticipated; and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," "will," "working" and similar expressions. Forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of the Company to timely and successfully achieve or recognize the anticipated benefits of its acquisition of Tenet Medicines, Inc. and the Agreement; changes in applicable laws or regulation; the possibility that the Company may be adversely affected by other economic, business and/or competitive factors; the Company's ability to advance budoprutug and CLYM116 on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approval
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Climb Bio, Inc. Date: January 10, 2025 By: /s/ Aoife Brennan Aoife Brennan, M.B., Ch.B. President and Chief Executive Officer